Rockefeller Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$63.3K Buy
5,309
+14
+0.3% +$240 ﹤0.01% 3322
2026
Q2
$128K Hold
5,295
– – ﹤0.01% 2842
2026
Q1
$87.1K Buy
5,295
+4,234
+399% +$81K ﹤0.01% 2957
2025
Q4
$16.6K Buy
+1,061
New +$14.3K ﹤0.01% 3591

Other funds holding GLUE

Rockefeller Capital Management's GLUE Position: Q3 2026 in Review

Rockefeller Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 0.26% in Q3 2026, buying an estimated $240 and bringing the position to 5,309 shares worth $63.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3322.

Rockefeller Capital Management first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $128K in Q2 2026. 189 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Rockefeller Capital Management held 5,309 shares of Monte Rosa Therapeutics worth $63.3K as of Q3 2026.
  • Rockefeller Capital Management bought 14 Monte Rosa Therapeutics shares in Q3 2026, an estimated $240.
  • Monte Rosa Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3322 holding.
  • Rockefeller Capital Management first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Monte Rosa Therapeutics position peaked at $128K in Q2 2026.
  • 189 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.